RxDoctor Payments Data

Ginel Gordon, NP

Nurse Practitioner · Rochester, NYNPI 1891288551

Payments from drug & device makers

$306in general payments, 2019–2025

Across 11 payments — averaging $27.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka Pharmaceutical Development & Commercialization, Inc.$90
  • Otsuka America Pharmaceutical, Inc.$67
  • Avanir Pharmaceuticals, Inc.$50
  • Acadia Pharmaceuticals Inc$44
  • AstraZeneca$40
  • Xeris Pharmaceuticals, Inc.$14

What the payments were for

  • Food & beverage$306100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$306 in reported general payments places this provider in the 75th percentile of 4,112 nurse practitioner providers in New York.

See all nurse practitioner providers in New York

Medicare billing

Part B allowed, 2024
$385,477
Medicare patients
452
Services billed
4,128

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban72$30,029
EntrestoSacubitril/Valsartan27$9,387
JanuviaSitagliptin Phosphate20$8,630
JardianceEmpagliflozin23$8,253
LokelmaSodium Zirconium Cyclosilicate24$7,857
SantylCollagenase Clostridium Hist.18$7,342
XareltoRivaroxaban11$5,731
Sevelamer Carbonate27$4,487
Sodium Chloride0.9 % Sodium Chloride45$3,257
Ursodiol19$2,614
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog23$2,462
Cefepime Hcl13$2,446
Pregabalin16$2,416
Meropenem14$2,143
Autoshield Duo Pen NeedlePen Needle,dual Safety,diabetc13$1,350

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaLokelma$40$7,85724 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,112 nurse practitioner providers in New York.

Other nurse practitioner in Rochester

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →